The Rising Demand for Outsourcing is Driving Growth in the U.S. Contract Research Organization (CROs) Market

The U.S. contract research organization (CROs) market provides a range of clinical trials and other research services to pharmaceutical and biotech companies. CROs help conduct preclinical testing, clinical trials, product regulatory approvals, and other services to help their clients develop and market drug and medical devices. The services offered by CROs help pharmaceutical and biotech companies reduce costs and focus internal resources on drug development.



The U.S. contract research organization (CROs) market is estimated to be valued at USD 21.85 Bn in 2025 and is expected to reach USD 49.56 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 12.4% from 2025 to 2032.

Key Takeaways



Key players

Key players operating in the U.S. CROs market are IQVIA, LabCorp, PAREXEL International, PRA Health Sciences, Syneos Health Inc, and Medpace. IQVIA is one of the largest CROs globally and provides a range of services including data management, biostatistics and more. PAREXEL International is another top CRO focused on bioanalytical, bioavailability services.



Growing demand

U.S. Contract Research Organization (CROs) Market Demand for CRO services is growing due to increasing R&D investment by pharmaceutical and biotech companies. Increased outsourcing of clinical trials and other drug development functions have also fueled market growth. Furthermore, the growing regulatory requirements for drug development have made CRO's an attractive option for streamlining operations.



Global expansion

Leading U.S. CROs like IQVIA, LabCorp and Syneos Health have expanded globally through acquisitions to cater to the growing international clientele. They have established facilities across developed markets in Europe and Asia as well as emerging markets like Latin America and Middle East. This global expansion allows CROs to reduce costs and conduct multi-regional clinical trials for clients.



Market Key Trends

The increasing adoption of virtual/decentralized clinical trials is a key trend in the U.S. CROs market. Due to the COVID-19 pandemic, there is a rise in demand for virtual/remote clinical trial solutions. CROs are investing in technologies like eClinical solutions, wearable devices and telehealth to recruit patients and collect data remotely without physical site visits. This allows clinical trials to achieve greater patient reach while maintaining social distancing norms.

Porter's Analysis



Threat of new entrants: Low barriers to entry but high capital investment requirements pose challenges to new players in the market.



Bargaining power of buyers: Pharmaceutical and biotechnology companies hold strong bargaining power as buyers due to the concentrated nature of demand in the market.



Bargaining power of suppliers: Suppliers of specialized testing services and clinical trial investigator sites hold moderate bargaining power.



Threat of new substitutes: New technological developments in clinical trials and drug discovery possess a potential threat of substitution.



Competitive rivalry: Intense rivalry exists among major CROs to win contracts from top pharmaceutical companies through competitive pricing and service differentiation.



Geographical Regions



North America currently accounts for the largest share of the global CRO market in terms of value, with the U.S. being the major revenue generator. Presence of many pharmaceutical giants and biotech companies driving clinical trials in the region attributes to its large market share.



Asia Pacific region is poised to be the fastest growing market during the forecast period. Factors such as lower costs for conducting clinical trials as well as the rapidly increasing patient population has attracted several pharmaceutical companies to outsource research activities to Asian CROs. Countries such as China and India are preferred global outsourcing destinations.

Get This Report in Japanese Language -米国の受託研究機関（CRO）市場

Get This Report in Korean Language - 미국 계약 연구 기관(CRO) 시장

About Author:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.

(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)